{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T03:48:48Z","timestamp":1743133728156,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":23,"publisher":"Springer New York","isbn-type":[{"type":"print","value":"9781493933457"},{"type":"electronic","value":"9781493933471"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/978-1-4939-3347-1_6","type":"book-chapter","created":{"date-parts":[[2016,2,24]],"date-time":"2016-02-24T04:04:49Z","timestamp":1456286689000},"page":"75-85","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dynamics of Expression of Drug Transporters: Methods for Appraisal"],"prefix":"10.1007","author":[{"given":"Marta","family":"Gromicho","sequence":"first","affiliation":[]},{"given":"Jos\u00e9","family":"Rueff","sequence":"additional","affiliation":[]},{"given":"Ant\u00f3nio Sebasti\u00e3o","family":"Rodrigues","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,2,25]]},"reference":[{"key":"6_CR1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2174\/138920112799857549","volume":"13","author":"AS Rodrigues","year":"2012","unstructured":"Rodrigues AS, Dinis J, Gromicho M et al (2012) Genomics and cancer drug resistance. Curr Pharm Biotechnol 13:651\u2013673","journal-title":"Curr Pharm Biotechnol"},{"key":"6_CR2","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1007\/s00018-008-8111-5","volume":"65","author":"H Lage","year":"2008","unstructured":"Lage H (2008) An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 65:3145\u20133167","journal-title":"Cell Mol Life Sci"},{"key":"6_CR3","first-page":"237","volume":"1775","author":"J-P Gillet","year":"2007","unstructured":"Gillet J-P, Efferth T, Remacle J (2007) Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 1775:237\u2013262","journal-title":"Biochim Biophys Acta"},{"key":"6_CR4","first-page":"5269","volume":"60","author":"GL Scheffer","year":"2000","unstructured":"Scheffer GL, Kool M, Heijn M et al (2000) Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res 60:5269\u20135277","journal-title":"Cancer Res"},{"key":"6_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/2040620712468289","volume":"4","author":"PK Bhamidipati","year":"2013","unstructured":"Bhamidipati PK, Kantarjian H, Cortes J et al (2013) Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol 4:103\u2013117","journal-title":"Ther Adv Hematol"},{"key":"6_CR6","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/cncr.25656","volume":"117","author":"E Jabbour","year":"2011","unstructured":"Jabbour E, Cortes J, Kantarjian H (2011) Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. Cancer 117:897\u2013906","journal-title":"Cancer"},{"key":"6_CR7","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F et al (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054\u20131061","journal-title":"Leukemia"},{"key":"6_CR8","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H Lavallade de","year":"2008","unstructured":"de Lavallade H, Apperley JF, Khorashad JS et al (2008) Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26:3358\u20133363","journal-title":"J Clin Oncol"},{"key":"6_CR9","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","volume":"112","author":"D Marin","year":"2008","unstructured":"Marin D, Milojkovic D, Olavarria E et al (2008) European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112:4437\u20134444","journal-title":"Blood"},{"key":"6_CR10","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","volume":"12","author":"S Soverini","year":"2006","unstructured":"Soverini S, Colarossi S, Gnani A et al (2006) Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 12:7374\u20137379","journal-title":"Clin Cancer Res"},{"key":"6_CR11","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F et al (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111:4022\u20134028","journal-title":"Blood"},{"key":"6_CR12","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G et al (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109:3496\u20133499","journal-title":"Blood"},{"key":"6_CR13","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","volume":"110","author":"DL White","year":"2007","unstructured":"White DL, Saunders VA, Dang P et al (2007) Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110:4064\u20134072","journal-title":"Blood"},{"key":"6_CR14","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1080\/10428190701858823","volume":"49","author":"RE Clark","year":"2008","unstructured":"Clark RE, Davies A, Pirmohamed M et al (2008) Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma 49:639\u2013642","journal-title":"Leuk Lymphoma"},{"key":"6_CR15","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/sj.leu.2404638","volume":"21","author":"C Brendel","year":"2007","unstructured":"Brendel C, Scharenberg C, Dohse M et al (2007) Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 21:1267\u20131275","journal-title":"Leukemia"},{"key":"6_CR16","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","volume":"104","author":"H Burger","year":"2004","unstructured":"Burger H, van Tol H, Boersma AWM et al (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump. Blood 104:2940\u20132942","journal-title":"Blood"},{"key":"6_CR17","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1158\/0008-5472.CAN-03-3344","volume":"64","author":"PJ Houghton","year":"2004","unstructured":"Houghton PJ (2004) Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64:2333\u20132337","journal-title":"Cancer Res"},{"key":"6_CR18","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1182\/blood-2005-10-4020","volume":"108","author":"T Nakanishi","year":"2006","unstructured":"Nakanishi T, Shiozawa K, Hassel BA et al (2006) Complex interaction of BCRP\/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood 108:678\u2013684","journal-title":"Blood"},{"key":"6_CR19","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.3109\/10428194.2011.584005","volume":"52","author":"M Gromicho","year":"2011","unstructured":"Gromicho M, Dinis J, Magalh\u00e3es M et al (2011) Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1. Leuk Lymphoma 52:1980\u20131990","journal-title":"Leuk Lymphoma"},{"key":"6_CR20","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.3109\/10428194.2012.681654","volume":"53","author":"J Dinis","year":"2012","unstructured":"Dinis J, Silva V, Gromicho M et al (2012) DNA damage response in imatinib resistant chronic myeloid leukemia K562 cells. Leuk Lymphoma 53:2004\u20132014","journal-title":"Leuk Lymphoma"},{"key":"6_CR21","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3892\/or.2012.2153","volume":"29","author":"M Gromicho","year":"2013","unstructured":"Gromicho M, Magalh\u00e3es M, Torres F et al (2013) Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib. Oncol Rep 29:741\u2013750","journal-title":"Oncol Rep"},{"key":"6_CR22","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402\u2013408","journal-title":"Methods"},{"key":"6_CR23","first-page":"93","volume":"125","author":"S Branford","year":"2006","unstructured":"Branford S, Hughes T (2006) Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med 125:93\u2013106","journal-title":"Methods Mol Med"}],"container-title":["Methods in Molecular Biology","Cancer Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-3347-1_6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T11:32:35Z","timestamp":1559388755000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-3347-1_6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9781493933457","9781493933471"],"references-count":23,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-3347-1_6","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2016]]},"assertion":[{"value":"25 February 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}